Aprea Therapeutics Inc (NAS:APRE)
$ 0.79 -0.018 (-2.18%) Market Cap: 9.79 Mil Enterprise Value: -36.67 Mil PE Ratio: 0 PB Ratio: 0.23 GF Score: 30/100

Aprea Therapeutics Inc Acquisition Of Atrin Pharmaceuticals Inc M&A Call Transcript

May 16, 2022 / 08:30PM GMT
Release Date Price: $19.26 (-19.09%)
Operator

Good day, and thank you for standing by. Welcome to the Aprea Therapeutics Update Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I would now like to hand the conference over to Gregory Korbel. Sir, please begin.

Gregory A. Korbel
Aprea Therapeutics AB - Chief Business Officer

Thank you, operator. Good afternoon, everyone. This is Greg Korbel, Chief Operating Officer at Aprea Therapeutics. And on behalf of the entire Aprea team, I'd like to welcome you to today's call. I'm joined today for our presentation by Chris Schade, Aprea's CEO; Dr. Oren Gilad, formerly Atrin's CEO; and now Aprea's President; and Dr. Eric Brown, Associate Professor of Cancer Biology at the University of Pennsylvania.

Before we get started, just a few administrative details. We intend to answer any questions at the end of the prepared remarks. Please feel free to submit a question at any time during the presentation by clicking on "Ask a Question" in your browser window, type a question into the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot